Janux Therapeutics, Inc.
JANX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $11 | $8 | $9 | $4 |
| % Growth | 31% | -6.1% | 136.8% | – |
| Cost of Goods Sold | $2 | $2 | $1 | $0 |
| Gross Profit | $9 | $6 | $8 | $4 |
| % Margin | 80.5% | 75.8% | 90.2% | 100% |
| R&D Expenses | $68 | $55 | $53 | $26 |
| G&A Expenses | $41 | $26 | $22 | $10 |
| SG&A Expenses | $41 | $26 | $22 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2 | -$2 | -$1 | $0 |
| Operating Expenses | $107 | $79 | $75 | $37 |
| Operating Income | -$99 | -$73 | -$67 | -$33 |
| % Margin | -933.6% | -902.9% | -779% | -905.4% |
| Other Income/Exp. Net | $30 | $15 | $4 | $0 |
| Pre-Tax Income | -$69 | -$58 | -$63 | -$33 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$69 | -$58 | -$63 | -$33 |
| % Margin | -651.6% | -721.2% | -732.2% | -898.3% |
| EPS | -1.28 | -1.32 | -1.52 | -0.79 |
| % Growth | 3% | 13.2% | -92.4% | – |
| EPS Diluted | -1.28 | -1.32 | -1.52 | -0.79 |
| Weighted Avg Shares Out | 54 | 44 | 41 | 41 |
| Weighted Avg Shares Out Dil | 54 | 44 | 41 | 41 |
| Supplemental Information | – | – | – | – |
| Interest Income | $30 | $15 | $4 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $2 | $1 | $0 |
| EBITDA | -$97 | -$71 | -$66 | -$33 |
| % Margin | -914.1% | -878.7% | -769.3% | -902.3% |